Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)

Manjunath, Meghana; Choudhary, Bibha

doi:10.3892/ol.2021.12773

Cited by 59 publications

(57 citation statements)

References 181 publications

(212 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our data, TNBC patients had the worst outcome, the efficacy was similar to other study 36 .The reason might be because of the mixed subtypes of TNBC 37 . How to improve therapeutic effects for TNBC patients become an important issue.…”

Section: Discussionsupporting

confidence: 85%

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Liu¹,

Hsieh²,

Su³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Advanced breast cancer (ABC) has become a chronic disease. In such a situation, an effective therapy with low toxicities and economically acceptable is needed. Metronomic vinorelbine (mVNR) has been proved to be effective on the control of MBC. The aim of this study is to evaluate the efficacy and safety of mVNR as the salvage therapy for patients with ABC. Oral vinorelbine (VNR) was administered at 70 mg/m2, fractionated on days 1, 3, and 5, for 3 weeks on and 1 week off. Once the mVNR was combined with trastuzumab, or was combined with bevacizumab, the schedule was changed to 2 weeks on and 1 week off. Clinical data of patients with ABC who had received treatment with mVNR and tumor characteristics were collected and analyzed. From Mar. 2013 to Dec, 2020, there were 90 patients with ABC received mVNR. The overall response rate was 53.3% and overall disease control rate (DCR) was 78.9% in this study, including 4 (4.4%) cases reached complete response, 44 (48.9%) cases reached partial response and 23 (25.6%) cases were table disease. The median time to treatment failure (TTF) of the Lumina A patients was 13.3 months, Lumina B patients was 9.1 months, Her-2 enrich patients was 8.9 months, and triple negative breast cancer (TNBC) patients was 5.6 months. Median overall survival time for Lumina A, Lumina B, Her-2 enrich and TNBC were 54.6 months, 53.3 months, 59.5 months and 24.5 months separately. Side effects were minimal and manageable. Metronomic VNR can be an effective treatment for ABC either works as a switch maintenance or salvage therapy. In combination with target therapy or hormonal therapy, mVNR can further improve TTF and DCR with minimal toxicities. Further study should focus on the optimal dosage, schedule and combination regimen.

show abstract

Section: Discussionsupporting

confidence: 85%

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Liu¹,

Hsieh²,

Su³

et al. 2021

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Nevertheless, TNBC is highly heterogenous and can show varied response. Due to this, a tailored approach based on clear understanding of subtype-specific response is crucial [ 47 ]. The observed significant reduction in tumorigenicity in all tested cancer cell lines proves the potential of combined PARPi Auger emitter strategy irrespective of subtype.…”

Section: Discussionmentioning

confidence: 99%

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study

Sankaranarayanan

Peil

Vogg

et al. 2022

Cancers

View full text Add to dashboard Cite

PARP1 inhibitors (PARPi) are currently approved for BRCAmut metastatic breast cancer, but they have shown limited response in triple negative breast cancer (TNBC) patients. Combination of an Auger emitter with PARPis enables PARP inhibition and DNA strand break induction simultaneously. This will enhance cytotoxicity and additionally allow a theranostic approach. This study presents the radiosynthesis of the Auger emitter [125I] coupled olaparib derivative: [125I]-PARPi-01, and its therapeutic evaluation in a panel of TNBC cell lines. Specificity was tested by a blocking assay. DNA strand break induction was analysed by γH2AX immunofluorescence staining. Cell cycle analysis and apoptosis assays were studied using flow cytometry in TNBC cell lines (BRCAwt/mut). Anchorage independent growth potential was evaluated using soft agar assay. [125I]-PARPi-01 showed PARP1-specificity and higher cytotoxicity than olaparib in TNBC cell lines irrespective of BRCA their status. Cell lines harbouring DNA repair deficiency showed response to [125I]-PARPi-01 monotherapy. Combined treatment with Dox-NP further enhanced therapeutic efficiency in metastatic resistant BRCAwt cell lines. The clonogenic survival was significantly reduced after treatment with [125I]-PARPi-01 in all TNBC lines investigated. Therapeutic efficacy was further enhanced after combined treatment with chemotherapeutics. [125I]-PARPi-01 is a promising radiotherapeutic agent for low radiation dosages, and mono/combined therapies of TNBC.

show abstract

“…Breast cancer (BC) is a heterogeneous disease with molecularly distinct subtypes displaying different clinical outcomes and responses to therapies [ 1 ]. Patients with “triple-negative” breast cancer (TNBC, lacking the expression of estrogen and progesterone receptors and Her2 overexpression) are mainly treated with conventional chemotherapies [ 1 , 2 ]. However, these patients have the worst prognosis as their treatment is challenging, due to their inter- and intra-tumor heterogeneity, leading to resistance to chemotherapy and relapse [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer

Suresh

Huard

Brisson

et al. 2022

Cancers

View full text Add to dashboard Cite

Identifying new therapeutic strategies for triple-negative breast cancer (TNBC) patients is a priority as these patients are highly prone to relapse after chemotherapy. Here, we found that protein arginine methyltransferase 1 (PRMT1) is highly expressed in all breast cancer subtypes. PRMT1 depletion decreases cell survival by inducing DNA damage and apoptosis in various breast cancer cell lines. Transcriptomic analysis and chromatin immunoprecipitation revealed that PRMT1 regulates the epidermal growth factor receptor (EGFR) and the Wnt signaling pathways, reported to be activated in TNBC. PRMT1 enzymatic activity is also required to stimulate the canonical Wnt pathway. Type I PRMT inhibitors decrease breast cancer cell proliferation and show anti-tumor activity in a TNBC xenograft model. These inhibitors display synergistic interactions with some chemotherapies used to treat TNBC patients as well as erlotinib, an EGFR inhibitor. Therefore, targeting PRMT1 in combination with these chemotherapies may improve existing treatments for TNBC patients.

show abstract

Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)

Cited by 59 publications

References 181 publications

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer

Contact Info

Product

Resources

About